Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 4/20 | 0.43 |
| ▸ | DRD2 | P14416 | 4/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | GHSR | Q92847 | 1/20 | 0.40 |
| ▸ | KDM4A | O75164 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.38 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.38 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6184913 | 0.86 | NAMPT (0.41) | NAMPTDRD2IDO1GHSRKDM4A | |
| SCHEMBL6185852 | 0.80 | NAMPT (0.44) | NAMPTDRD2IDO1GHSRKDM4A | |
| SCHEMBL508325 | 0.79 | HCRTR2 (0.42) | DRD2 | |
| SCHEMBL23874419 | 0.79 | GHSR (0.35) | NAMPTGHSREPHX2MAPK10 | |
| SCHEMBL28055196 | 0.77 | HCRTR2 (0.40) | DRD2NPFFR1NPFFR2 | |
| SCHEMBL16463082 | 0.76 | EPHX2 (0.45) | NAMPTDRD2GHSREPHX2MAPK10 | |
| SCHEMBL5962444 | 0.76 | EPHX1 (0.41) | DRD2 | |
| SCHEMBL18182483 | 0.73 | HCRTR2 (0.43) | DRD2 | |
| SCHEMBL18563739 | 0.73 | ALDH1A1 (0.44) | NAMPTDRD2IDO1GHSRKDM4A | |
| SCHEMBL16350191 | 0.71 | GHSR (0.46) | NAMPTDRD2GHSREPHX2MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256166-A1 | Nitrogen-containing compounds | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-11-17 | — | — | US | disclosed |
| EP-1535906-A1 | NITROGEN-CONTAINING COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256166-A1 | Nitrogen-containing compounds | DPP4, DPP3, DPP8 | NAMPT 212/4885DRD2 3114/4885IDO1 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.